In Clinical Development, Orphan Drug Congress, Orphan Drugs Live, Whitepapers by Freya Smale

Rare diseases present an array of challenges to patients, their families and caregivers, and physicians. Arriving at an early and accurate diagnosis is a rate limiting step to getting the patient the care they so desperately need. Most organizations focused on rare disorders agree that it takes several years for a patient with a rare disease to receive a proper diagnosis. For the undiagnosed or misdiagnosed patient struggling with a rare disease, this journey can be long, arduous, frustrating and expensive.

Download the whitepaper now

81qd, an advanced data analytics company at the forefront of rare disease analytics, has developed an innovative solution that could help shorten that journey for many patients. Orion™ is a rare disease analytic platform that uses machine learning technology to help identify patients with a high probability of having a specific rare disease so that they can ultimately be screened, clinically diagnosed and receive the appropriate care.

Download the whitepaper now

In a Q&A interview session, 81qd’s leadership discussed Orion, and the company’s other customized, high-value, cost-effective solutions for the life sciences industry. The following members of the management team shared their insights:

Leon Behar, PharmD, Chief Executive Officer
• Kelly Myers, Executive Vice President, Data Analytics
• Daniel Leskiewicz, PhD, Senior Vice President, Health Sciences & Applied Analytics

Download the whitepaper now

We are thrilled to announce that 81QD are joining us as a sponsor at this year’s World Orphan Drug Congress USA 2016. Register today to meet them in D.C. on April 20-22.

World Orphan Drug Congress USA 2016